Key Benefits

• Spot cancer-related sodium, calcium, and cortisol shifts that affect safety and treatment.
• Flag hyponatremia early; small-cell lung cancer can cause water retention, headaches, confusion, seizures.
• Catch high calcium fast; squamous lung cancers often raise calcium causing thirst and drowsiness.
• Clarify fatigue and weakness by separating electrolyte issues from anemia, infection, or progression.
• Guide urgent care needs; severe sodium or calcium shifts may require IV therapy.
• Monitor cortisol to detect adrenal insufficiency from immunotherapy, metastases, or steroid tapering.
• Support treatment planning by adjusting fluids, salts, bone-strengthening medicines, or steroids when needed.
• Track trends using morning cortisol; interpret alongside kidney function, medications, and hydration status.

What are Lung Cancer biomarkers?

Lung cancer biomarkers are traces of the tumor’s biology that appear in the blood and reveal what the cancer is doing and how best to treat it. As lung tumors grow and turn over, they release DNA fragments, proteins, and occasional whole cells into circulation. Blood tests can capture and decode these signals. DNA fragments from the tumor (circulating tumor DNA, ctDNA) carry the cancer’s instructions, including targetable changes such as EGFR, ALK, ROS1, and KRAS, as well as resistance mutations that emerge under therapy. Protein markers shed by tumor cells (CEA, CYFRA 21-1, NSE, ProGRP) and rare circulating tumor cells (CTCs) reflect tumor burden and cell death. Together, these biomarkers enable a “liquid biopsy”: a repeatable, low-risk way to characterize the tumor’s molecular drivers, select targeted drugs, monitor response, and detect relapse earlier than scans. They also offer clues to immunotherapy sensitivity, such as overall mutation load in blood (blood TMB). In short, lung cancer biomarkers turn the tumor’s biological whispers into actionable guidance throughout care.

Why is blood testing for Lung Cancer important?

Blood tests in lung cancer track biomarkers that signal tumor activity, paraneoplastic hormone release, tissue breakdown, and the body’s stress and immune responses. Beyond tumor markers such as CEA, CYFRA 21‑1, NSE, and ProGRP, routine chemistries and hormones reveal how the disease is influencing the brain, heart, kidneys, bones, and metabolism.For orientation, sodium generally runs 135–145, and calcium about 8.6–10.2, with most people healthiest near the middle. Cortisol follows a diurnal curve—high in the morning, low by evening—so “optimal” is about the right rhythm rather than a single number.When values fall, they tell a story. Low sodium often reflects SIADH from small‑cell lung cancer, where excess antidiuretic hormone traps water, diluting salts; people feel headache, nausea, confusion, or seizures as brain cells swell. Mildly lower sodium can appear in pregnancy, making symptoms easier to miss. Low calcium is less typical but may occur with vitamin D deficiency or extensive bone involvement, causing tingling, cramps, or spasms. If cortisol is low—sometimes from adrenal metastases—expect fatigue, weight loss, low blood pressure, and worsening hyponatremia.When values rise, different mechanisms are at play. High sodium points to water loss or diabetes insipidus from brain involvement, bringing intense thirst and mental clouding. High calcium, classic with squamous cell tumors via PTH‑related peptide, causes constipation, dehydration, confusion, arrhythmias, and kidney stones. Excess cortisol from ectopic ACTH in small‑cell disease drives muscle weakness, high glucose, infections, and in women irregular cycles; in children it can blunt growth.Big picture, these biomarkers integrate tumor biology with neuroendocrine, renal, and skeletal physiology. Tracking them alongside imaging refines prognosis, flags complications early, and links cancer behavior to long‑term risks like cognitive decline, fractures, kidney injury, and cardiometabolic strain.

What insights will I get?

Lung cancer blood testing provides insight into how the body’s core systems are coping with the presence of cancer. At a systems level, these tests help us understand the impact of lung cancer on energy balance, mineral metabolism, stress response, and overall physiological stability. At Superpower, we focus on three key biomarkers: sodium, calcium, and cortisol.Sodium is an essential electrolyte that helps regulate fluid balance, nerve function, and blood pressure. In lung cancer, abnormal sodium levels can signal disruptions in water balance or hormone production, sometimes due to the cancer itself or as a side effect of treatment. Calcium is vital for bone health, muscle contraction, and nerve signaling. Lung cancer can cause calcium levels to rise or fall, often reflecting changes in bone metabolism or the release of certain hormones by tumors. Cortisol is a hormone produced by the adrenal glands in response to stress. Elevated or suppressed cortisol levels in lung cancer may indicate how the body is managing chronic stress, inflammation, or the effects of cancer therapies.Together, sodium, calcium, and cortisol provide a window into the body’s ability to maintain stability—what medicine calls homeostasis—when challenged by lung cancer. Stable levels suggest the body is adapting well, while significant changes may point to complications or the need for closer monitoring.Interpretation of these biomarkers depends on several factors, including age, other medical conditions, medications, and even the specific laboratory methods used. Temporary changes can also occur with acute illness, dehydration, or recent treatments, so results are always considered in context.